Ken Song, RayzeBio CEO
September 13, 2022 11:17 AM EDTUpdated September 14, 04:18 AM
Financing

With fresh $160M, Rayze­Bio plots sprint through the clin­ic for lead ra­dio­phar­ma­ceu­ti­cal pro­gram — build­ing on No­var­tis' suc­cess

Amber Tong

Ever since its launch in 2020, Rayze­Bio has talked at length about build­ing a plat­form com­pa­ny to ful­fill the po­ten­tial that ra­dio­phar­ma­ceu­ti­cals hold …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times